相关实验视频

Updated: Jan 8, 2026

Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells

Murine Experimental Model of Original Tumor Development and Peritoneal Metastasis via Orthotopic Inoculation with Ovarian Carcinoma Cells

Published on: December 9, 2016

局部晚期乳腺癌:EUSOMA的经验

Peter van Dam¹, Mariano Tomatis², Antonio Ponti³

¹Multidisciplinary Oncologic Center, Antwerp University Hospital, Edegem, Belgium.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|December 14, 2025

概括

这项研究分析了局部晚期乳腺癌 (LABC) 病例,发现多模式治疗对于更好的生存结果至关重要. 放射治疗和内分泌治疗显著降低了LABC患者的局部复发率.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
临床医学临床医学

背景情况:

局部晚期乳腺癌 (LABC) 在治疗和预后方面存在独特的挑战.
了解临床病理特征和治疗模式对于改善患者的治疗结果至关重要.

研究的目的:

评估局部晚期乳腺癌 (LABC) 的临床病理特征.
评估用于LABC患者的治疗方式.
为了确定与LABC治疗相关的结果.

主要方法:

分析了来自欧洲乳腺癌专家协会 (EUSOMA) 数据仓库的数据.
包括患有临床局部晚期乳腺癌 (cLABC) 阶段cT4a-d在2013-2022年间的患者.
临床病理学特征,治疗干预措施和患者的结果被追溯审查.

主要成果:

在132,269名患者中,有2427人患有cT4abc乳腺癌 (BC),977人患有炎症性 (T4d) BC;分别有20.1%和25.6%患有转移性疾病.
在88%以上的cT4abcM0和cT4dM0患者中,使用了手术和内分泌治疗.
多变量分析确定了年轻的年龄 (<70岁),特定的亚型 (光线A,HER-2纯),手术,放射治疗和全身治疗作为改善整体存活率 (OS) 的预测因素.
放射治疗或内分泌治疗显著降低了局部复发率 (LRR).
在cT4abc和T4d BC患者之间没有观察到OS或LRR的显著差异.

结论:

这项研究证实了已知cLABCs的特征.
多模式治疗方法对于管理LABC至关重要.
在LABC患者中观察到综合多模式治疗的不足利用,突出显示需要改进治疗策略.

关键词:

化疗化疗是一种化学疗法.医疗保健医疗保健医疗保健医疗保健炎症性乳腺新生体的发生.局部发达的乳腺癌.新辅助疗法是一种新辅助疗法.质量指标质量指标

更多相关视频

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...